MAGE-A3161–175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells
Tóm tắt
We report here that HLA-DRβ4*01 restricted MAGE-A3161–175 specific CD4+ T cells from a healthy donor recognize a naturally processed epitope formed through the exogenous but not the endogenous pathway. However, the intensity of recognition of the native epitope by MAGE-A3161–175 specific CD4+ T cells strongly depends on the antigen presenting cells and the amount of protein available for processing. EBV-transformed lymphoblastoid cells (LCLs) and melanoma cells engineered to express MAGE-A3 in the endosomal/lysosomal compartment were strongly recognized while autologous dendritic cells loaded with lysate from MAGE-A3 expressing cells were, although significantly, poorly recognized. To prove that the amount of antigen available for processing was a key factor determining the different response LCLs were sorted by MAGE-A3 expression. The response intensity correlated with the amount of MAGE-A3 expressed by the cells. Collectively, these results suggest that different antigen presenting cells with different amount of antigen available for processing as well as protease activity are important factors in determining the epitope repertoire produced in vivo, and therefore reliable tools should be used when testing recognition of native epitopes by peptide specific CD4+ T cells.
Tài liệu tham khảo
Antoniou AN, Blackwood SL, Mazzeo D, Watts C (2000) Control of antigen presentation by a single protease cleavage site. Immunity 12:391–398
Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-A3 epitopes presented by HLA-DR molecules to CD4+ T lymphocytes. J Exp Med 189:767–778
Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101(3):1038–1044
Crosti M, Longhi R, Consogno G, Melloni G, Zannini P, Protti MP (2006) Identification of novel subdominant epitopes on the carcinoembryonic antigen recognized by CD4+ T cells of lung cancer patients. J Immunol 176(8):5093–5099
Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 64:565–571
Fleischhauer K, Tanzarella S, Russo V, Sensi ML, van der Bruggen P, Bordignon C, Traversari C (1997) Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol 159:2513–2521
Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930
Knutson KL, Disis ML (2005) Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord 5(4):365–371
Kobayashi H, Song Y, Hoon DSB, Appella E, Celis E (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61:4773–4778
Lich JD, Elliott JF, Blum JS (2000) Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med 191:1513–1523
Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:8871–8876
Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33:1250–1259
Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593–596
Pardoll DM, Topalian SL (1998) The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588–594
Pluger EB, Boes M, Alfonso C, Schroter CJ, Kalbacher H, Ploegh HL, Driesses C (2002) Specific role of cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 32:467–476
Protti MP, Manfredi AA, Straub C, Wu XD, Howard JF Jr, Conti-Tronconi (1990) Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. J Immunol 144(5):1711–1720
Schultz ES, Lethe B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60:6272–6275
Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G (2004) Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell based immunotherapy. J Immunol 172:1304–1310
Sercarz EE, Maverakis E (2003) Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 3:621–629
Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J (1999) Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555–561
Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4+ T cells and their role in antitumor immune response. J Exp Med 189:753–756
Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol 23:975–1028
van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognised by human T cells. Immunol Rev 188:51–64
Wack A, Montagna D, Dellabona P, Casorati G (1996) An improved PCR-heteroduplex method permits high sensitivity detection of clonal expansion in complex T cell population. J Immunol Meth 196:181–192
Zhang Y, Chaux P, Stroobant V, Eggermont AMM, Corthals J, Maillere B, Thielemans K, Marchand M, Boon T, van der Bruggen P (2003) A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171:219–225